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Abstract
Autosomal recessive cerebellar ataxia 2 (ARCA2) is a recently identified recessive ataxia due to ubiquinone deficiency
and biallelic mutations in the ADCK3 gene. The phenotype of the twenty-one patients reported worldwide varies
greatly. Thus, it is difficult to decide which ataxic patients are good candidates for ADCK3 screening without evidence
of ubiquinone deficiency. We report here the clinical and molecular data of 10 newly diagnosed patients from seven
families and update the disease history of four additional patients reported in previous articles to delineate the clinical
spectrum of ARCA2 phenotype and to provide a guide to the molecular diagnosis. First signs occurred before
adulthood in all 14 patients. Cerebellar atrophy appeared in all instances. The progressivity and severity of ataxia varied
greatly, but no patients had the typical inexorable ataxic course that characterizes other childhood-onset recessive
ataxias. The ataxia was frequently associated with other neurological signs. Importantly, stroke-like episodes contributed
to significant deterioration of the neurological status in two patients. Ubidecarenone therapy markedly improved the
movement disorders, including ataxia, in two other patients. The 7 novel ADCK3 mutations found in the 10 new
patients were two missense and five truncating mutations. There was no apparent correlation between the genotype
and the phenotype. Our series reveals that the clinical spectrum of ARCA2 encompasses a range of ataxic phenotypes.
On one end, it may manifest as a pure ataxia with very slow progressivity and, on the other end, as a severe infantile
encephalopathy with cerebellar atrophy. The phenotype of most patients, however, lies in between. It is characterized
by a very slowly progressive or apparently stable ataxia associated with other signs of central nervous system
involvement. We suggest undergoing the molecular analysis of ADCK3 in patients with this phenotype and in those
with cerebellar atrophy and a stroke-like episode. The diagnosis of patients with a severe ARCA2 phenotype may also
be performed on the basis of biological data, i.e. low ubiquinone level or functional evidence of ubiquinone deficiency.
This diagnosis is crucial since the neurological status of some patients may be improved by ubiquinone therapy.
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Introduction
Autosomal recessive cerebellar ataxias (ARCAs) are a
group of neurodegenerative disorders defined by a per-
sistent and gradually worsening disorder of gait and bal-
ance or with the development over months or years of
hypotonia or excessive clumsiness [1]. In most cases,
ARCAs start in childhood or adolescence and lead to a
loss of ambulation within 10-20 years. ARCA2 is a re-
cently identified entity reported in 21 patients worldwide
[2-6]. It is due to recessive mutations in the ADCK3/
CABC1 gene leading to coenzyme Q10 (CoQ10) defi-
ciency, and is also known as COQ10D4 and SCAR9 (spi-
nocerebellar ataxia recessive 9, MIM #612016). Given
the genetic heterogeneity of ARCAs, the identification of
key clinical features of ARCA2 is of particular import-
ance for physicians facing the diagnosis of an ataxic indi-
vidual. If the parents of the patient are healthy, the
hypothesis of a recessive ataxia is reasonable and mo-
lecular studies will be guided by clinical, radiological and
biological findings. On the other hand, if variants of un-
known significance are identified in ADCK3 with new
generation sequencing analyses, the diagnostic process
will be guided by their clinical relevance.
Previous articles showed that the ARCA2 phenotype
varied greatly from one patient to another. Indeed, the
neurological involvement appeared either as a pure ataxia
[4], or as progressive ataxia with cerebellar atrophy in
addition to intellectual deficiency, epilepsy, stroke-like
episodes (SLE) and/or exercise intolerance in some pa-
tients [4-7], or as a severe and progressive encephalopathy
comprising cerebellar atrophy in others [5]. Furthermore,
the ataxia seemed to be progressive in some patients and
apparently self-limited in others [2]. Thus, the ARCA2
phenotype remains difficult to define. Radiological data
did not provide any clue to the diagnosis, except that
stroke-like images may be observed [5]. The relevance of
biological data is limited by the conflicting results of
routine assays (lactacidemias, ubiquinone assays), but
muscular ubiquinone deficiency and mitochondrial re-
spiratory chain assessment seem to provide reliable clues
to the diagnosis [4-6]. Thus, to date, the decision to screen
ADCK3 mutations mainly relies on the evidence of mus-
cular ubiquinone deficiency.
We report the clinical history and molecular findings
in 10 new ARCA2 patients and provide detailed and
updated clinical data of four other patients previously re-
ported [4,5]. We compare our data with those of the lit-
erature in an attempt to facilitate the decision for ADCK3
molecular study and its interpretation in ataxic patients.
Material and methods
Patients
Since 2008, 419 patients affected by ataxia of unknown
etiology with cerebellar atrophy whose DNA was sent to
the diagnostic center were screened for ADCK3 muta-
tions (Dr Anheim and Dr Koenig). Biallelic mutations
were found in nine patients (all but patient #7). Molecular
diagnosis was made after ubiquinone deficiency was evi-
denced in patient #7 (Dr Rötig, Dr Lebre, Dr Desguerre,
Dr Pascale de Lonlay). All samples were collected
under informed consent. In addition on the ten patients,
we retrospectively reassessed clinical data from four
previously reported patients [4,5,7] and provide an
update of the outcome thanks to their referral neurol-
ogists. Patient #11 has been reported as patient 7 in
[4], patient #12 as patient 4 in [5,7], and patients #13
and #14 as patients 2 and 3, respectively, in [5].
Functional disability related to ataxia was evaluated
with the Spinocerebellar Degeneration Functional Score
[8,9] (SDFS: 0: no functional handicap; 1: no functional
handicap but signs at examination; 2: mild, able to run;
3: moderate, unable to run; 4: severe, walking with one
stick, unlimited walking; 5: walking with two sticks;
6: unable to walk, requiring a wheelchair; 7: bedridden).
When possible, the clinical severity of ataxia was evalu-
ated at last examination with the Scale for the Assess-
ment and Rating of Ataxia (SARA) [10]. We used the
Spearman rank correlation analysis to determine the
association between the SDFS/ SARA scores and the
duration of ataxia.
The Wechsler Intelligence Scale for Adults (WAIS) was
used to evaluate the intellectual quotient in adult patients
and the Wechsler Intelligence Scale for Children (WISC-
IV) was used for patient #13.
Movement disorders
Neurophysiological recording of movement disorders
was performed with a Neuropack (Nihon Kohden, Japan)
device. Movement was recorded with a unidirectional
piezo-resistive accelerometer (Acc) (PCB Piezotronics,
USA), Acc signal was band-pass filtered at 0.5100 Hz.
Electromyographic (EMG) signals were obtained from
pairs of silver/silver chloride electrodes (Medtronic,
Minneapolis, MN, USA) placed over muscle bellies,
and band pass filtered at 20-500 Hz. The selection of
recorded muscles was guided by the clinical location
of tremor (upper limb and/or or neck).Tremor was re-
corded during rest, posture and action/intention. The ef-
fect of mental calculation was tested at rest. Postural and
action/intention tremor were analysed during tonic con-
traction, slow elementary non goal-directed movements,
goal-directed movements and spiral drawing. Stimulus-
sensitive myoclonus was searched for with a slight distal
touch, a pinprick and passive mobilization of the wrist.
Dystonic features, namely co-contraction, overflow, spasms
and asymmetries were carefully evaluated. The frequency
of tremor and the bursts duration were measured by man-
ual analysis of EMG and Acc epochs.
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Molecular genetics
The 14 coding exons and the adjacent intronic junc-
tions of the human ADCK3 gene were amplified and
sequenced as detailed previously [4]. Sequences were ana-
lysed using the Seqpilot software version 2.0 (JSI medisys,
Kippenheim, Germany) or the Seqscape 2.5 software
(Applied Biosystems). Conservation of amino-acids in-
volved in missense mutations was analysed with the blastp
software of the NCBI platform (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) with the non-redundant protein sequences
(nr) database. The splice site mutation was analysed with
the SplicePort software (http://spliceport.cbcb.umd.edu/)
and by RT-PCR as detailed previously [4] using primers
located in exons 3 and 8 (forward 5- TCTTTGCAAA
CCCCAGAGAC -3, reverse 5- CCCAGGTCGTTGTT
GAGAGT -3).
Partial gene deletion was assessed with the Illumina
CytoSNP-12 arrays which contain 300,000 markers in-
cluding 200,000 SNPs according to the manufacturers
specifications (Illumina, San Diego, California, CA, USA).
Image data were analysed with the Chromosome Viewer
tool contained in Genome StudioV2001.1. The metrics
used were the Log R ratio (in ratio of the sample copy
number/reference copy number) and the B allele fre-
quency (BAF) (the genotype of each SNP). Genomic posi-




The 10 new patients with ADCK3 mutations identified
since the first report were six females and four males, in-
cluding six individuals from three unrelated sibships and
four sporadic cases. Nine over 14 ARCA2 patients re-
ported here were adults at the time diagnosis, three were
adolescents and two were children. Nine mutations were
found, including five homozygous and seven novel mu-
tations. Clinical and molecular data of the 14 patients
are available in Additional file 1: Table S1. A detailed de-
scription of representative clinical histories (patients #3,
#5, #6 and #7) is available online as Additional file 2.
ARCA2 onset
First clinical manifestations occurred at a mean age of
6.7 years (range 1.5-19 years), with obvious signs before
or at 15 years in 11/13 patients. Gait ataxia was the first
clinical manifestation in 8/14 patients at a mean age of
10.1 years (range 2.5-15 years). Cerebellar ataxia was
obvious after the age of walking in all patients but one
who never walked (patient #7). In this patient, truncal
ataxia was rapidly associated with global developmental
regression.
Clinical signs in the upper limbs were prominent at
disease onset in 7/14 patients (mean age 5 years, range
2-15 years) in the form of clumsiness of hands, writing
difficulties, hand dystonia or chorea. Obviously, the ori-
gin of some of signs may have been cerebellar, particu-
larly when associated with gait ataxia. In other cases (4/7
patients), they preceded gait ataxia by 3 to 7 years.
Severe exercise intolerance was the first sign of ARCA2
in patient #12 (previously reported in [7]).
The course of ataxia
In our patients series, mean age at last examination was
26.2 years (range 5-44 years) with mean disease duration
of 19.4 years (range 3.5-34 years). Excluding patient #7
who never walked, mean duration of ataxia for the 13
other patients was 18.5 years (range 8-34 years, median
15 years). All these patients were ambulatory except pa-
tient #13 who had to use a walking aid after a SLE. The
semi-quantitative SARA score was assessed during the last
examination for 10 patients (Additional file 1: Table S1),
ranging from 4 to 15.5/40 (mean 10.7, standard deviation
3.8). SARA scores were not apparently correlated with the
age of ataxia onset and with the duration of ataxia when
known (9/10) (Figure 1, bottom left), which was con-
firmed by the Spearman rank correlation analysis (rho
values -0.23 and -0.15, respectively). Likewise, the func-
tional scores were 1.5 to 7 (mean SDFS 2.8), irrespec-
tively of the duration of ataxia (Figure 1, top left, rho
values -0.13 for ataxia onset and -0.21 for ataxia duration).
The patients, their parents and/or their pediatric medical
records allowed a retrospective evaluation of the func-
tional score for nine of them (Figure 1, top right). It mildly
worsened over a period of 12 to 29 years in two pa-
tients, which may be partially explained by the con-
comitant muscular involvement in patient #12 and by
the occurrence of a SLE in patient #13 [5]. In patient
#7 the severity of functional outcome was extreme
from the onset. In five other patients, the functional
score was remarkably stable and mild over a mean
period of 18.6 years (range 10-30 years).
Patients with a severe neurological phenotype
Patient #7 with severe neurodegeneration from infancy
is the only patient of our series with this phenotype.
All ARCA2 features reported in other patients with a
mild severity (epilepsy, dystonia, pyramidal syndrome,
intellectual deficiency) were present in patient #7 but
with a much more severe intensity. Her brain MRI
disclosed global brain atrophy, not only cerebellar
atrophy.
Patients #5 and #13 [5] had a single SLE at the ages of
34 and 14 years, respectively. In both cases, it presented
as a status epilepticus with residual epilepsy and deteri-
oration of intellectual and motor functions in patient
#13, and with residual partial visual loss in patient #5.
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Clinical features associated with ataxia
Movement disorders and polymyographic recordings
Movement disorders unrelated to the cerebellar syn-
drome were present in 9/14 patients of our series and
sometimes combined in the same patient: myoclonus in
6/14, dystonia in 6/14, chorea in 2/14 and tremor in 2/14
(Additional file 1: Table S1). In one patient, unilateral dys-
tonia was as the consequence of a SLE (patient #13). In
the others, hand or neck dystonia was mild, could be fluc-
tuating, clinically significant in daily life, and reportedly
stable with time. Patient #10 had hand chorea from the
age of 2 to 7 years, the age at which gait ataxia appeared.
Erratic myoclonus were observed in 6/14 patients and
tremor in three. Myoclonic jerks were of low amplitude
but obvious at examination. Polymyographic recording
disclosed mild myoclonus and tremor in neck muscles
suggesting dystonic tremor in patient #3 (Figure2A), and
myoclonus associated with mild hand dystonia in patient
#12. Here, myoclonic jerks were absent at rest, not
elicited by tactile or pinprick distal stimuli nor wors-
ened with action, had no peculiar temporo-spatial
organization. They were longer (80-135 ms) than ex-
pected for a cortical generator. No abnormalities were
found in patients #5 and #6 though dystonia and
Figure 1 Disability scoring and stroke-like lesions in patients with ARCA2. Functional Score (SDFS, top left) and Scale for the Assessment
and Rating of Ataxia (SARA, bottom left) evaluated during the last examination are presented according to the duration of ataxia in 13 and 9
patients (numbered #1 to #14), respectively. Patient #7 with infantile global brain degeneration clearly stands out from other patients with the
mild phenotype (top left). SDFS and SARA scores do not appear to be correlated with the duration of ataxia, as confirmed by the Spearman rank
correlation analysis (see text). The evolution of the SDFS with time was determined in nine patients (top right). It did not change during
childhood, from childhood to adulthood and throughout adulthood in 7/9 patients. Patients #12 is the unique patient with muscular
involvement, which may explain the worsening of the SDFS score with time. The neurological status of patient #13 worsened after a SLE, and
then partially recovered. Bottom right subpanel: brain MR images of patient #5 showed vermian atrophy (A, T1-weighted image) and stroke-like
lesions of the occipital lobe during the episode (B, FLAIR sequence). These images were attenuated one week after (C) the episode and no longer
visible seven weeks later (D).
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tremor were clinically diagnosed a few hours after re-
cording, which was in line with the reported fluctuations.
A regular postural/action tremor (frequency 6 Hz, bursts
duration 110 ms) was recorded in the upper limbs in pa-
tient #4 (Figure 2C).
Corticospinal tract involvement
Most patients had brisk tendon reflexes (11/14), two had
a unilateral or bilateral plantar extensor reflex. Spasticity
was disclosed only in patients #7 and #13, i.e. in one pa-
tient with severe brain degeneration and another with a
SLE (hemiparesis in her case). The pyramidal syndrome
did not appear to have functional consequences in other
examined patients of our series.
Seizures/epilepsy and EEG
7/14 patients experienced seizures. Patient #12 had a
single episode in childhood and never received any
anti-epileptic drug (AED). Three patients had few sei-
zures before the age of 20 years and received an AED
without seizure relapse. AED have been successfully
withdrawn in two of them. The two patients with a
SLE with epileptic manifestations previously had well-
controlled epilepsy. Patient #7 had severe drug-resistant
epilepsy.
Though most seizures were reported as generalized
tonic-clonic, interictal EEG recordings showed focal (4/8)
or multifocal (1/8) spikes and/or spike-waves. The back-
ground activity was altered in patient #7 only.
Early development and intellectual functioning
Most patients (9/13) had a normal initial development
during their first three years, i.e. acquired walking ability,
language learning and an accurate use of hand in time.
3/13 had a mildly delayed acquisition of walking and/or
a language delay. Finally, a global regression was ob-
served at 18 months in patient #7 described above.
8/14 adult or adolescent patients were considered not
to have an intellectual deficiency (ID), 5/14 to have mild
ID, and patient #7 had an obvious profound ID. Formal
Figure 2 Polymyographic recordings of tremor and myoclonus in two patients with ARCA2 demonstrating the effect of ubidecarenone
therapy. Patient #3: note the erratic myoclonus (*) obtained in SCM muscles (90 ms), during writing (A). Dystonic tremor (arrow), can be seen in
posterior muscles (right and left splenius), intermingled with myoclonus (◊). All these abnormalities were absent after treatment (B). Patient #4:
left upper limb recording performed during spiral drawing displayed a 6 Hz regular tremor (arrow), composed of 120 ms length bursts, alternating in
antagonistic forearm muscles (ECR/FCR), associated to an oscillatory signal in Acc (C). Note the dramatic attenuation of tremor amplitude after
treatment on spiral drawing (D, before treatment and E, under ubidecarenone), as well as on polymyographic recording (F, under treatment).
Abbreviations: r: right, l: left, SCM: sterno-cleido-mastoideous, ECR: extensor carpi radialis, FCR: flexor carpi radialis, FDI: first dorsal interosseous muscles,
Acc: accelerometer.
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evaluation in patients #3 and #4 confirmed normal intel-
lectual functioning. Mild ID was confirmed in patients
#11 (FSIQ 54, WAIS) and in patient #13 before the SLE
(FSIQ 70, WISC-IV).
Muscular involvement
The only patient reported here with muscular involve-
ment is patient #12 whose disease has been extensively
detailed by others [7]. She is now 20 years, her muscular
involvement is stabilized and she needs no walking aid.
Other paraclinical tests
Brain MRI
In all patients, brain MRI disclosed cerebellar atrophy
without cerebellar signal anomalies or any other specificity.
It is not clear whether it was present from the onset of
ataxia. The two patients with a SLE had MRI anomalies of
the affected part of the cerebral cortex, i.e. of the parietal
(reported in [5]) or occipital lobes (Figure 1, bottom right).
Global brain atrophy was found in patient #7 with severe
involvement.
Mitochondrial disease investigations
Plasma lactic acid levels were normal in 9/10 patients
and increased in the patient with muscular involvement
[7]. CSF lactic acid concentrations were normal in 8/8
patients. The assessment of mitochondrial oxidative
phosphorylation showed normal enzyme activity in the
muscle of patient #8 and a deficiency of complex II + III
in patients #11 [7] and #7. Co-enzyme Q10 (CoQ10, ubi-
quinone) levels were normal in the fibroblasts of two pa-
tients and decreased in the blood of patient #7 and in
the muscle of patient #11 [7]. Over the five patients who
underwent a muscle biopsy, three had a normal patho-
logical aspect and two had ragged-red fibres, i.e. patient
#7 with severe involvement and patient #11 with muscu-
lar involvement.
Molecular analysis of the ADCK3 gene
All patients carried biallelic alterations of ADCK3
(Additional file 1: Table S1) with a total of nine different
mutations. Mutations inducing aminoacid substitutions
were c.811C > T (p.Arg271Cys), c.895C > T (p.Arg299Trp),
c.1523 T > C (p.Phe508Ser) and c.1844G > A (p.Gly615
Asp). Truncating mutations were c.1081-1_1082dupGTA
(p.Gln360_Tyr361ins*), c.1358delT (p.Leu453Argfs*24),
c.1228C > T (p.Arg410*), c.589-3C > G (p.Leu197Valfs*20)
and a 29 kb partial deletion of the gene including at least
exons 3 to 15 (base pair position: 227,150,977-227,195,656,
hg19).
The mutation c.1081-1_1082dupGTA is a 3-nucleotide
duplication overlapping the acceptor splice site of exon 9.
It does not alter the splice site but results in a 3-nucleotide
insertion at the beginning of exon 9 which immediately
creates an in-frame stop codon (p.Gln360_Tyr361ins*).
The homozygous c.589-3C > G mutation lying in in-
tron 3 and found in sisters #8 and #9 affects the ac-
ceptor splice site of exon 4. It reduces the splicing score
predicted with the SplicePort software from 3.02 to 1.53.
ADCK3 transcript analysis from the patients fibroblasts,
who are homozygous for the mutation, indicates that
usage of the normal exon 4 acceptor splice site is com-
pletely abolished and replaced by the usage of a cryptic
splice site located 23 nucleotides upstream, causing a
frame-shift and termination 20 codons after the last
codon of exon 3 (p.Leu197Valfs*20). The SplicePort spli-
cing score of the cryptic splice site is 2.11, explaining
why it is preferably used over the mutant splice site but
not over the normal splice site.
Ubiquinone supplementation therapy
Twelve patients received ubiquinone supplementation
therapy: 10 received ubidecarenone with doses varying
from 100 mg × 3/day to 250 mg × 3/day and 30 mg/kg/
d in patient #7, and two patients received idebenone at
45 mg × 3/day. No clear improvement was noticed in
seven patients. In patient #12, the myoclonus was aggra-
vated by idebenone. She recovered her previous status
after its withdrawal and received ubidecarenone without
clear improvement. Ubidecarenone had to be withdrawn
in two patients who experienced reversible side effects
(anorexia and diarrhea). The outcome is not known for
one patient.
Two patients took advantage from ubidecarenone
therapy. Patient #3 had a dramatic and long-lasting im-
provement of dystonia and myoclonus after six months
of treatment confirmed by polymyographic recording
(Figure 2B). His SARA score improved from 9.5 to 6.5.
Likewise, the polymyographic recording of the tremor of
patient #4 improved after 8 months, as well as his draw-
ing ability (Figure 2E and 2F).
Discussion
The description of the phenotype in the 14 patients re-
ported here together with that of other patients of the
literature (Additional file 3: Table S2) allows us to give
an accurate picture of the ARCA2 from the first signs to
adulthood and throughout adulthood.
Variability of onset
First clinical manifestations of ARCA2 occurred at a
mean age of 6.7 years in our series and at 19 years for
the oldest patients. This is in line with the mean age of
6.6 years reported in 17 patients of the literature. Hence,
ARCA2 mostly starts in childhood or adolescence, some-
times in early adulthood. The only exception (patient 2 in
[3]) is a woman with adult-onset ataxia (46 years), but she
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experienced seizures in childhood, which may have been
the first manifestation of ARCA2.
Like in our series, gait ataxia was the most frequent sign
at disease onset in 11/14 patients of the literature, but diffi-
culties with the use of hands were reported only twice [2,3].
Though the origin of hand clumsiness may have been cere-
bellar, particularly when associated with gait ataxia, this
was not the case for all of our patients. Our series study
suggests that dystonia or chorea of hands may be the first
manifestations of ARCA2 in some patients. Other manifes-
tations were rarer at disease onset, including exercise in-
tolerance in patient #12 and epilepsy in three patients of
the literature [3,6]. Taken together, these data indicate that
the onset of ARCA2 is not stereotyped but manifests most
often as early-onset ataxia, and sometimes as hand clumsi-
ness or as epilepsy. Non-ataxic presentations may be mis-
leading until ataxia or cerebellar atrophy is evidenced.
Mild disease course in most patients
Since gait ataxia was the main criterion for ADCK3 mu-
tation screening, it was present in all patients reported
to date, suggesting a possible screening bias. Despite
phenotypical heterogeneity, it is noteworthy that all 10
affected sibs of seven probands reported so far also had
gait ataxia, suggesting that cerebellar syndrome may be
the common feature of all ARCA2 patients. Gait ataxia
was associated with other cerebellar signs in the patients
of our series as well as in most patients of the literature,
when indicated, i.e. upper limb dysmetria, dysarthric
speech and saccadic ocular pursuit.
Regarding the course of ataxia, the semi-quantitative
evaluations of ataxia and disability gave strikingly mild
scores in most patients, including in the elders. The
slight progressivity or stability of ataxia in ARCA2 from
childhood to adulthood and throughout adulthood has
been previously suggested by other authors [2,3]. Indeed,
data from the literature suggest a favorable ataxic out-
come, since 14/17 patients were still ambulatory when
reported after a mean ataxia history of 20.8 years
(range 5-34 years, median 27.5 years). Among the three
previously reported patients who became wheelchair
bound, one had a SLE [5], like the significantly dis-
abled patient #13 of our series, and two other had a
global neurological regression from the ages of 1.5
and 3 years (patients 3 and 4 in [3]), like patient #7 re-
ported here.
The mean SARA score in the 10 evaluated ARCA2 pa-
tients reported here is 10.7 after a mean duration of
19.4 years (ratio SARA/disease duration = 0.55 point/
year). Most other genetic progressive ataxias are associ-
ated with a more unfavorable outcome. As an example,
patients with Friedreich ataxia (whose first signs occur
later than in ARCA2) have a mean SARA score of 22.7 ± 9
after mean disease duration of 17.3 ± 9.2 years (ratio 1.3
point/year) [11]. In ataxia with ocular apraxia type 2
(AOA2), the mean SDFS score is 4.7 after a mean disease
duration of 18.9 years [12], giving a mean progression rate
of the disability score (SDFS/disease duration) of 0.39
versus 0.19 for the 13 ARCA2 patients evaluated here.
Moreover, in other ARCAs, deambulation is lost after a
mean disease duration of 10 years in ataxia telangiectasia,
10-15 years in Friedreich ataxia and about 20 years in
AOA2 [1], which contrasts with the 26/31 (83%) ambula-
tory ARCA2 patients affected for a mean duration of
18.6 years. Moreover, the slow evolution of ARCA2 ataxia
is obvious when compared with dominant spinocerebellar
ataxias (SCA) due to polyglutamine tract expansion in
which the mean SARA score is 14.9 after a disease dur-
ation of 11 years (ratio 1.35 point/year) [13]. The mean
SARA score of non polyglutamine-related SCAs is how-
ever closer to that of ARCA2, with a value of 11 after
16 years for (ratio 0.68 point/year) [13].
These data indicate that the progression of ataxia in
ARCA2 is usually mild and that the neurological out-
come in most ARCA2 patients is not an inexorable evo-
lution towards loss of ambulation, unlike in most other
ARCAs with childhood onset.
At the other end of the spectrum, patients with a severe
phenotype
In most patients, the unfavorable outcomes in ARCA2
patients of our series and of the literature were neither
related to the worsening of cerebellar signs, nor to its as-
sociation with spastic paraparesis or peripheral neur-
opathy, as it is the case in other ARCAs [1].
SLEs, which have been reported in several mitochon-
drial disorders [14,15], may explain the severity of the
ARCA2 phenotype in 3/31 patients. SLEs were reported
in two patients of the literature (both in [5], including
patient #13 reported here) and occurred during adoles-
cence as a single episode without relapse. In both cases,
it presented as a status epilepticus with residual epilepsy
and deterioration of intellectual and motor functions.
Patient #5 reported in our series experienced a posterior
SLE at the age of 34 years while her ataxia and epilepsy
remained stable (Additional file 2). This suggests that
some ARCA2 patients with an apparently stable disease
may experience acute and disabling events at any age. In
her particular case, the SLE could have been the conse-
quence of a metabolic stress due to significant weight
loss. While neurological functions declined after SLE in
patients #5 and #13, the neurological involvement in
their siblings was still limited and stable. This is consist-
ent with SLE being an important factor that may explain
the heterogeneity of the functional outcome among af-
fected siblings.
The phenotype of patient #7 is more suggestive of an
infantile degenerative encephalopathy rather than
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progressive ataxia. Given parental consanguinity, we
could not exclude an associated genetic factor that
could possibly explain this unique phenotype among
the patients of our series. However, a similar pheno-
type has been reported by others (patients 3 and 4 in
[3]), which confirms that early global neurological re-
gression is the most extreme presentation of ARCA2.
It is worth mentioning that ARCA2 in other patients
with an onset before three years had a relatively mild
disease course (family B in Gerards et al., 2010),
meaning that an early onset does not necessarily indi-
cate a severe phenotype.
We conclude that, like in many other mitochondrial
disorders, the severity of the neurological involvement
in ARCA2 is variable, with about 19% of patients (6/31)
being significantly disabled either because of a SLE or be-
cause their phenotype is a severe progressive encephalop-
athy rather than a degeneration of the cerebellum.
ARCA2: a complex phenotype
Ataxia was the only sign of ARCA2 in 3/31 patients only
(patient 1 of family 1 and patient 5 of family 2 in [4] and
patient #2 reported here). Most patients, however, pre-
sented neurological signs in addition to ataxia.
Movement disorders (dystonia, myoclonus, tremor)
were present in 9/14 patients our series and were also
reported in previous articles: dystonia in four cases
[2-4], myoclonus in three [2,3] and tremor in two [3].
Hand chorea observed in patient #10 from the age of 2
to 7 years is the only choreic ARCA2 patient reported to
date and is a striking example of spontaneous neuro-
logical improvement with time. Six patients of our series
had myoclonic jerks but they were reported in only three
patients of the literature (total 9/31). Their frequency
may have been underestimated since they were of low
amplitude in most of our patients, some of them being
evidenced with polymyographic recording.
Though pyramidal signs were present in most patients
of our series (11/14), two patients only had a significant
spasticity. Pyramidal signs are also frequently reported
in patients from the literature (6/11, totally 17/25) but
spasticity was reported in 3/15 (totally 5/31). Thus, spas-
tic ataxia is not a usual presentation in the phenotypic
spectrum of ARCA2.
6/14 patients in our series and 5/17 in the literature
had epilepsy (totally 11/31). Seizures were controlled by
AEDs or transient in half of the epileptic patients re-
ported here and in other previously reported ones [3,6].
Seizures dramatically worsened in three patients during
and after a SLE (patients #5 and #13 and patient 1 in
[5]) and was drug-resistant in one patient with infantile
encephalopathy (patient #7). Therefore, the severity of
epilepsy in ARCA2 is as variable as ataxia, with most
patients being mildly affected as long as a SLE does not
occur.
Intellectual deficiency (ID) unrelated to a SLE was re-
ported in 7/14 ARCA2 patients of the literature and in
8/14 in our series. It was mild in 9 patients and moder-
ate to severe in 4 (patient #7, [2-6]). It is possible that
up to one half of ARCA2 patients have an ID but formal
evaluations are obviously lacking, at least in patients
with mild ID.
The prominent muscular involvement in patient #12
seems to be unique [7]. Exercise intolerance or muscle
weakness was reported in 11/17 patients of the litera-
ture. It is not clear, however, whether these patients had
acute muscle weakness and myolysis during exercise.
The frequency of true exercise intolerance or myop-
athy in ARCA2 still has to be evaluated.
Paraclinical tests in ARCA2
We report for the first time polymyographic recordings
of patients with ARCA2. Our data show that movement
disorders in ARCA2 are variable and include subcortical
myoclonus, dystonia and tremor. It is worth mentioning
that myoclonus in ARCA2 are of low amplitude and less
disabling than cortical myoclonus recorded in progres-
sive myoclonic epilepsies, with which ARCA2 shares
some features [16,17].
Cerebellar atrophy was present in all reported ARCA2
patients to date and global brain atrophy in two patients
with severe involvement (patient #7 and patient 3 in
[3]). As discussed above, cerebellar atrophy is expected
from the patients of our series screened from an ataxic
cohort. The finding of stroke-like lesions on brain MRI
in a patient with cerebellar atrophy (like in patients #5
and #13 also reported in [5]) is undoubtedly a clue for
the diagnosis of ARCA2. However, stroke-like lesions
may attenuate and disappear with time (Figure 1, bottom
right).
Since ARCA2 is due to ubiquinone deficiency, mito-
chondrial disease investigations are particularly expected
to provide clues to the diagnosis. Like in our patients
series, the concentration of lactic acid was normal in the
plasma [4,6] (totally n = 22/27), as well as in the CSF (to-
tally n = 8/9) of most patients. These assays are poorly
indicative of ARCA2, except in case of muscular involve-
ment (patient #12, also in [7]). The relevance of ubiquin-
one assays is conflicting, since it was normal in the
fibroblasts of 3/5 patients and low in two others [4,5],
low in the blood of one patient and in the muscle of the
four patients tested so far [4-6]. From this limited num-
ber of patients, muscular level of ubiquinone seems to
be the most reliable biological parameter to suggest
ARCA2. The assessment of the activity of mitochondrial
respiratory chain enzymes suggested CoQ10 deficiency
in all analysed muscle samples (patient #7, [2,5-7], but
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one (patient #8), and in the fibroblasts of some patients
[4]. Therefore, when necessary, biological studies per-
formed with muscle samples are undoubtedly the most
efficient for the diagnosis of ARCA2.
Spectrum of ADCK3 mutations
The p.Arg271Cys and p.Arg299Trp mutations were
already reported missense mutations [3]. Since these two
missense mutations occur on CpG dinucleotides, which
are potential mutation hot-spots, they may represent re-
current mutational events rather than cases resulting
from founder events. All other mutations reported here
are novel. Two missense mutations alter the highly con-
served DFG (Asp-Phe-Gly) motif VII of the kinase
domain (p.Phe508Ser) and a highly conserved glycine
residue in the C-terminal domain specific of the ADCK3-
ADCK4 subfamily (p.Gly615Asp; glycine 615 is conserved
in all eukaryotes and in all bacteria having an ADCK3/
ADCK4 orthologue). The five other mutations are
truncating mutations, including two of them found in
intron/exon boundaries (c.1081-1_1082dupGTA and c.589-
3C >G).
There is no apparent correlation between mutations
and severity of the disease. Indeed, some homozygous
truncating mutations (patients #8 and #9) and heterozy-
gous missense associated with a frameshift mutation (pa-
tients #3, #4, #5 and #6) can be associated with a relatively
mildly progressive disease, while some homozygous mis-
sense mutations are associated with a very severe pheno-
type (patient #7) or a mild phenotype (patients #1 and #2).
Ubiquinone/CoQ10 supplementation therapy
Because CoQ10 deficiency is the cause of ARCA2, it is
logical to anticipate clinical improvement with ubiquin-
one supplementation therapy with either idebenone or
ubidecarenone. Seven ARCA2 patients reported so far
received idebenone at different doses ranging from
200 mg to 700 mg per day for adults and 10 mg/kg/day
for children. The treatment was evaluated after two
months to three years and was considered either ineffi-
cient [3], or efficient [4,6], or even harmful [5,7]. Regard-
ing our series, ubiquinone therapy did not lead to
significant improvement of the neurological status in
most patients. This could be due to the slow clinical
course and mild impairment in these patients. Ubidecar-
enone had reversible side effects in some patients but
did not worsen the neurological involvement, in oppos-
ition to idebenone in two patients (patient #12 and patient
1 in [5]). Strikingly, movement disorders were markedly
improved in two patients reported here under ubidecare-
none. Therefore, we would suggest the use of ubidecare-
none rather than idebenone but it is obviously too early to
definitively conclude on the effectiveness or the ineffect-
iveness of CoQ10 supplementation in ARCA2 and further
study are needed to assess such efficacy. In particular,
whether ubidecarenone is efficient in preventing SLE is an
important issue without answer to date.
When to ask for ADCK3 molecular study?
It appears from the analysis of the 31 ARCA2 patients
known to date that the condition encompasses a broad
phenotypic spectrum. The ataxia is mostly associated
with other neurological signs (movement disorder, pyr-
amidal involvement, epilepsy, ID), rarely with muscular
involvement but not with peripheral neuropathy, and is
mildly progressive or apparently stable from childhood
to adulthood and throughout adulthood. The severity of
associated signs seems to be proportionate with that of
the ataxia and the phenotype may be aggravated by a
SLE in some patients. On the other hand, a minority of
patients may have a severe encephalopathy with global
brain degeneration and atrophy.
The study of muscular samples from ARCA2 patients
proved to be reliable for its diagnosis. Although fully jus-
tified given the severe clinical involvement in some pa-
tients, as discussed by others [6], it may be regarded as
too invasive in most patients with mild disability.
We suggest undergoing first the targeted molecular
analysis of ADCK3 in mildly affected individuals with a
suspected ARCA when the phenotype is compatible, in-
cluding in ataxic patients experiencing a SLE. The diag-
nosis of other patients with an atypical and/or severe
ARCA2 phenotype may also be performed on the basis
of biological data, i.e. when low ubiquinone muscular
level or functional ubiquinone deficiency is evidenced.
Obviously, diagnosis tools using next generation sequen-
cing, such as massively parallel sequencing of targeted
genes [18] or exome sequencing [19], which are already
or will be soon used for ARCAs, will modify the molecu-
lar diagnosis strategy. In these cases, knowledge of the
heterogeneous phenotypes associated with mutations in
ADCK3 will be helpful to interpret these results [20].
Additional files
Additional file 1: Table S1. Clinical, biological, molecular and
radiological data from 14 patients with ARCA2.
Additional file 2: Clinical, biological, molecular and radiological
data from 17 ARCA2 patients of the literature.
Additional file 3: Table S2. Detailed description of representative
clinical histories.
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